Glycoconjugates: What It Would Take To Master These Well-Known yet Little-Understood Immunogens for Vaccine Development.

Avci, Fikri; Berti, Francesco; Dull, Peter; Hennessey, John; Pavliak, Viliam; Prasad, A Krishna; Vann, Willie; Wacker, Michael; Marcq, Olivier

Avci, Fikri; Berti, Francesco; Dull, Peter; Hennessey, John; Pavliak, Viliam; Prasad, A Krishna; Vann, Willie; Wacker, Michael; Marcq, Olivier.

Afiliación

Avci F; Department of Biochemistry and Molecular Biology, Center for Molecular Medicine and Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA.
Berti F; GSK Vaccines, Siena, Italy.
Dull P; Bill and Melinda Gates Foundation, Seattle, Washington, USA.
Hennessey J; Independent Researcher, Lower Gwynedd, Pennsylvania, USA.
Pavliak V; International Vaccines Institute (IVI), Seoul, Republic of Korea.
Prasad AK; Citranvi LLC, Chapel Hill, North Carolina, USA.
Vann W; FDA-CBER, Silver Spring, Maryland, USA.
Wacker M; Wacker Biotech Consulting, Thalwil, Switzerland.
Marcq O; Sutrovax, Foster City, California, USA omarcq@sutrovax.com.

mSphere ; 4(5)2019 09 25.

Article en En | MEDLINE | ID: mdl-31554723

Asunto(s)

Vacunas Bacterianas/inmunología; Glicoconjugados/inmunología; Vacunas Bacterianas/química; Investigación Biomédica; Glicoconjugados/química; Humanos; Vacunas Conjugadas

Palabras clave

T-cell immunity; capsular polysaccharide; carrier protein; clinical trials; glycoconjugates; immunity; immunology; infectious disease; synthetic drug carriers; vaccines

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Glicoconjugados / Vacunas Bacterianas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: MSphere Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google